<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335767">
  <stage>Registered</stage>
  <submitdate>20/05/2011</submitdate>
  <approvaldate>30/05/2011</approvaldate>
  <actrnumber>ACTRN12611000547943</actrnumber>
  <trial_identification>
    <studytitle>PRINCess: The  Prediction of Regression in CIN2 - The Conservative Management of Cervical Intraepithelial Neoplasia (CIN) 2 in Young Women</studytitle>
    <scientifictitle>PRINCess: The  Prediction of Regression in CIN2 - A prospective study of young women under the age of 25 with biopsy proven CIN2 undergoing conservative management with assessment of regression, stable disease and progression.</scientifictitle>
    <utrn>U1111-1116-3209</utrn>
    <trialacronym />
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cervical Intraepithelial Neoplasia (CIN) 2</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Cervical (cervix)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Conservative Management for Cervical Intraepithelial Neoplasia (CIN) 2 for 24 months i.e. six monthly colposcopy and cervical biopsy for a total of two years</interventions>
    <comparator>No treatment</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression rates of CIN 2 in women under the age of 25. Progression will be detected at colposcopy in conjunction with smear and biopsy.</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Regression rates of CIN 2 in women under the age of 25.
Regression will be detected at colposcopy in conjunction with smear and biopsy.</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To identify the safety of follow-up, as opposed to surgical management, of CIN 2, in young women under the age of 25.
The outcome is either progression, regression or no change after 2 years - all assessed by colposcopy, smear and biopsy.</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The correlation of CIN 2 with immunohistochemical parameters: P16, Proex, Ki67, HPV typing will be assessed.</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compliance with follow-up will also be assessed as an outcome measure.
Compliance will be assessed by attendance at clinic, routine prompts to clinic will be allowed.</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All women up to the age of 25 attending colposcopy clinics  with biopsy proven CIN 2 with the entire lesion accessible at colposcopy.  Participants in this study must agree to six monthly colposcopy and cervical biopsy for a total of two years.</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>25</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria include those women with higher grade cervical intraepithelial neoplasia and findings suspicions for invasion on colposcopic assessment.  Adenocarcinoma-in-situ is an exclusion category as is incomplete colposcopy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>30/04/2010</anticipatedstartdate>
    <actualstartdate>14/04/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>19/10/2016</actualenddate>
    <samplesize>600</samplesize>
    <actualsamplesize>617</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/10/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>The Royal Women's Hospital - Parkville</hospital>
    <hospital>The Chris Oâ€™Brien Lifehouse - Camperdown</hospital>
    <postcode>3052 - Parkville</postcode>
    <postcode>2050 - Camperdown</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago - Christchurch</primarysponsorname>
    <primarysponsoraddress>Private Bag 4711
Christchurch 8140</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Otago - Christchurch</fundingname>
      <fundingaddress>Private Bag 4711
Christchurch 8140</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Canterbury District Health Board</fundingname>
      <fundingaddress>Private Bag 4710 
Christchurch  8140</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cancer Society of New Zealand, Canterbury West Coast Division</fundingname>
      <fundingaddress>PO Box 13450
Christchurch</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council NZ</fundingname>
      <fundingaddress>PO Box 5541
Wellesley Street
Auckland 1141</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Canterbury District Health Board</sponsorname>
      <sponsoraddress>Private Bag 4710 
Christchurch  8140</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Cervical intraepithelial neoplasia 1, 2 or 3 is the term used to describe a range of cellular changes on the cervix that over time can regress to normal or progress to cervical cancer.  Cervical cancers are usually preceded by a long phase of preinvasive disease.  Evidence has shown that there is a 43% likelihood of regression of CIN 2, a 35% likelihood of persistence of CIN 2 and a 20% probability of progression to CIN 3.  Evidence in adolescents has shown an even higher rate of regression.  The current treatment for this abnormality is a LLETZ biopsy of the cervix.  This treatment is associated with complications in future pregnancies  premature rupture of membranes and preterm labour.  Because of the high regression rate and pregnancy complications, young women, up to age 25, with biopsy proven CIN 2 at Christchurch and Dunedin Hospitals will be offered inclusion in the study.  This will involve 6 monthly colposcopy clinic visits where a cervical smear, biopsy and tests for HPV, Proex, P16, Ki67 as opposed to immediate surgical management.  If there is progression of this change to CIN 3 throughout follow-up a LLETZ will be offered.  Follow-up is for 24 months  if the CIN 2 abnormality persists, LLETZ will be offered.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>The trial has recruited women in many New Zealand hospitals.</publicnotes>
    <ethicscommitee>
      <ethicname>Multiregion Ethics Committee - New Zealand</ethicname>
      <ethicaddress>PO Box 5013
Wellington</ethicaddress>
      <ethicapprovaldate>14/04/2010</ethicapprovaldate>
      <hrec>MEC/09/07/079</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ethics Review Committe (RPAH Zone)</ethicname>
      <ethicaddress>Research Development office
Royal Prince Alfred Hospital
Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate>14/11/2013</ethicapprovaldate>
      <hrec>13/RPAH/352</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Associate Professor Peter Sykes</name>
      <address>Christchurch Womens Hospital
Private Bag 4710
Christchurch</address>
      <phone>+64 3 3644630</phone>
      <fax>+64 3 3644634</fax>
      <email>peter.sykes@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Ms Dianne Harker</name>
      <address>Private Bag 4711
Christchurch</address>
      <phone>+64 3 3644624</phone>
      <fax>+64 3 3644634</fax>
      <email>dianne.harker@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dianne Harker</name>
      <address>Private Bag 4711
Christchurch</address>
      <phone>+64 3 3644624</phone>
      <fax>+64 3 3644634</fax>
      <email>dianne.harker@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Peter H Sykes</name>
      <address>University of Otago - Christchurch
Department of O &amp; G
Private Bag 4711
Christchurch 8140</address>
      <phone>+64 3 364 4630</phone>
      <fax>+64 3 364 4634</fax>
      <email>peter.sykes@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>